<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423474</url>
  </required_header>
  <id_info>
    <org_study_id>50-2011</org_study_id>
    <nct_id>NCT01423474</nct_id>
  </id_info>
  <brief_title>Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time</brief_title>
  <acronym>PATRIOT</acronym>
  <official_title>Randomized Phase II Study of 2 Hypofractionated Radiotherapy Schedules for Low- and Intermediate-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CancerCare Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the toxicity of two new radiation schedules for the
      treatment of prostate cancer. Patients will be randomized to receive 5 treatments delivered
      every other day over 11 days, or once per week over 29 days. Both of these schedules are
      shorter than the standard treatment which is usually 39 treatments over 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel related quality-of-life</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal toxicity</measure>
    <time_frame>During radiotherapy, at 3 and 6 months, then every 6 months after</time_frame>
    <description>Radiation Therapy Oncology Group Acute and Late Morbidity Scoring Schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genitourinary toxicity</measure>
    <time_frame>During radiotherapy, at 3 and 6 months, then every 6 months after</time_frame>
    <description>Radiation Therapy Oncology Group Acute and Late Morbidity Scoring Schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA relapse rate</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>During radiotherapy, at 3 and 6 months, then every 6 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage androgen deprivation therapy rate</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Short treatment time (11 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Long treatment time (29 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image-guided radiotherapy</intervention_name>
    <description>40 Gy / 5 fractions / 11 days</description>
    <arm_group_label>Short treatment time (11 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image-guided radiotherapy</intervention_name>
    <description>40 Gy / 5 fractions / 29 days</description>
    <arm_group_label>Long treatment time (29 days)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low or intermediate risk prostate cancer patients as defined by:

               -  Clinical stage T1-2b, Gleason Score &lt;=7, and PSA &lt;=20 ng/mL

          -  Age &gt;= 18 years

        Exclusion Criteria:

          -  Androgen deprivation therapy (LHRH-agonists or antiandrogens) &gt;6 months

          -  Prior pelvic radiotherapy

          -  Anticoagulation medication (if unsafe to discontinue for gold seed insertion)

          -  Diagnosis of bleeding diathesis

          -  Large prostate (&gt;90cm3) on imaging

          -  Immunosuppressive medications

          -  Inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldrich Ong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CancerCare Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Loblaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Agency - Abbotsford Centre</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CancerCare Manitoba</investigator_affiliation>
    <investigator_full_name>Dr. Aldrich Ong</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Hypofractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

